Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab, Lenalidomide, and Dexamethasone +/- Cyclophosphamide for Relapsed AL Amyloidosis
NCT03252600Phase 2Unknown
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Aug 2017
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elotuzumab in light-chain amyloidosis, sponsored by Barbara Ann Karmanos Cancer Institute. Status: unknown.
02
Drugs
elotuzumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT03252600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252600.